Sign in
Taking people in NetherlandsPhase 3

Testing atomoxetine for freezing episodes when walking in Parkinson's disease

Tests atomoxetine on walking freezes in adults with Parkinson's disease.

Key facts

Who runs it
Stichting Radboud universitair medisch centrum
Where
Nijmegen, NetherlandsSee the 2 sites
Registry title
Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.
Status
Recruiting
Phase
Phase 3
People taking part
20 people, planned
Started
19 Jan 2026
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease who have freezing of gait every day. It tests whether atomoxetine reduces freezing in the dopaminergic OFF-state.

Age
18 years or older
Sex
Men and women
Disease stage
Idiopathic Parkinson's disease (Movement Disorders Society criteria) with freezing of gait symptoms every day. Must be able to walk 10-meters unaided in the dopaminergic ON-state.
Earlier treatment
Must be stable on optimal dopaminergic treatment for at least four weeks before the baseline visit. Cannot be taking noradrenergic agents, CYP2D6 inhibitors (SSRIs, quinidine, terbinafine) or high dose salbutamol (or other beta2 agonists).

Main reasons for not taking part

  • Taking part in another clinical trial now or within the past 3 months
  • History of pheochromocytoma, narrow angle glaucoma, or known allergy to atomoxetine
  • Severe heart, blood vessel or brain blood vessel disease, or liver or kidney insufficiency
  • Pregnancy or breastfeeding
  • Cannot have an MRI scan, or severe memory or thinking problems or active psychosis

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Male or female aged 18 years or older
  • Diagnosis of idiopathic Parkinson's disease according to Movement Disorders Society Diagnostic Criteria
  • Stabilised on optimal dopaminergic treatment for a minimum of four weeks prior to the baseline visit (Visit 1)
  • Presence of freezing of gait symptoms on a daily basis
  • Ability to walk for 10-meters unaided in the dopaminergic ON-state
  • Ability to provide written informed consent in accordance with ICH-GCP and local regulations
  • Willing and able to undergo all clinical trial assessments

Who cannot take part

  • Current and/or previous (within 3 months) participation in a clinical trial
  • Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine)
  • (History of) pheochromocytoma
  • Known hypersensitivity to atomoxetine
  • Severe cognitive impairment hampering the ability to comply with the study protocol
  • Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke
  • Hepatic or renal insufficiency
  • Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long QT interval syndrome (QTc > 500ms zettBa-formula) and channelopathies that would significantly compromise participant safety
  • Use of noradrenergic agents
  • Use of high dose salbutamol (or other beta2 agonists)
  • Pregnancy and/or breastfeeding
  • Any contra-indications for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker)
  • Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments)
  • Active psychosis that would impact the ability to comply with the study protocol
  • Narrow angle glaucoma

Where in Netherlands

  • Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people
  • Radboud Universiteit NijmegenNijmegen, NetherlandsTaking people

About the trial

What the trial wants to find out

To study the effect of atomoxetine FOG severity in the dopaminergic OFF-state.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.
Plain-language title
Testing atomoxetine for freezing episodes when walking in Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 May 2026